“This study gives new insights into developing high performance intranasal vaccine systems with two-dimensional sheet-like nanoparticles,” Dong said. “The graphene oxide nanoparticles have extraordinary attributes for drug delivery or vaccine development, such as the ultra-large surface area for high-density antigen loading, and the vaccine showed superior immunoenhancing properties in vitro and in vivo. The nanoplatform could be easily adapted for constructing mucosal vaccines for different respiratory pathogens.
“…these kinds of nanoparticles would appear to have the potential to cause harm to organic matter, plants, fish, animals, and humans. The affected area could be quick to spread, and could take some time to become safe again.
“The situation today is similar to where we were with chemicals and pharmaceuticals 30 years ago,” said the paper’s co-author Jacob D. Lanphere. “We just don’t know much about what happens when these engineered nanomaterials get into the ground or water. So we have to be proactive so we have the data available to promote sustainable applications of this technology in the future.”
At this stage, the Material Safety Data Sheet governing the industrial use of graphene is incomplete. It’s listed as a potential irritant of skin and eyes, and potentially hazardous to breathe in or ingest. No information is available on whether it has carcinogenic effects or potential developmental toxicity.”